WO1985004397A1 - Regulateur de croissance apparente aux thrombocytes - Google Patents

Regulateur de croissance apparente aux thrombocytes Download PDF

Info

Publication number
WO1985004397A1
WO1985004397A1 PCT/US1985/000480 US8500480W WO8504397A1 WO 1985004397 A1 WO1985004397 A1 WO 1985004397A1 US 8500480 W US8500480 W US 8500480W WO 8504397 A1 WO8504397 A1 WO 8504397A1
Authority
WO
WIPO (PCT)
Prior art keywords
carbon atoms
amino acid
aliphatic
amino acids
polar
Prior art date
Application number
PCT/US1985/000480
Other languages
English (en)
Inventor
Daniel R. Twardzik
George J. Todaro
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/592,969 external-priority patent/US4590003A/en
Application filed by Oncogen filed Critical Oncogen
Priority to HU852180A priority Critical patent/HU210662B/hu
Priority to KR1019850700309A priority patent/KR910000735B1/ko
Priority to EP85902216A priority patent/EP0176588B1/fr
Priority to JP60501854A priority patent/JPH0816063B2/ja
Priority to DE3587863T priority patent/DE3587863T2/de
Publication of WO1985004397A1 publication Critical patent/WO1985004397A1/fr
Priority to FI854604A priority patent/FI92258C/fi
Priority to DK198505406A priority patent/DK172463B1/da
Priority to FI940457A priority patent/FI940457A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues

Definitions

  • Polypeptide compositions and their use are provided which are characterized by having at least one of the following properties: capable of inhibiting tumor growth, while not inhibiting normal cell growth; capable of stimulating pp60 src autophosphorylation; capable of inducing secretion of a 52kDal protein from tumor cells; and having a substantially equivalent amino acid sequence of at least a portion of a polypeptide isolatable from mammalian platelets and exhibiting at least one of the previously-indicated properties.
  • the polypeptides are provided in substantially pure form.
  • compositions comprising polypeptides, derivatives, fragments, or analogs thereof and formulations containing such compositions are provided which effect mammalian neoplastic cell growth inhibition.
  • the subject polypeptides are related to a naturally occurring polypeptide in the ethanolic HCl fraction obtained by extraction of platelets, called in the literature platelet factor 4 and referred to as
  • the polypeptides are stable at moderate temperatures (0-25°C), at a low pH, generally below about pH 3, usually at pH 2.
  • the polypeptides have a molecular weight in the range of about 5,000-8,000, more exactly in the range of about 6,000-7,500, more particularly about 7,000.
  • This polypeptide is obtained from platelets of higher mammals, particularly primates, more particularly humans.
  • polypeptide compounds which are employed will have from about 15 to 80 amino acids, where the naturally occurring polypeptides and mimetic analogs thereof will have from about 60 to 75 amino acids, more usually from about 65 to 72 amino acids, while fragments will generally range from about 15 to 60 amino acids, more usually from about 15 to 35 amino acids.
  • These polypeptides may be joined to other compounds, such as antigens, receptors, labels, or the like.
  • the polypeptides will have at least one biologically active sequence, e.g., immunological or epitopic, and may have more than one biologically active sequence, where such sequence can compete with a naturally occurring product for the biological property.
  • compositions of interest will have an acidic (anionic) N-terminus and a basic (cationic) C-terminus, where the charged regions will be from 6 to 15 amino acids, usually 6 to 12 amino acids, where the region will include an amino acid sequence of from 6 to 8 amino acids where at least 50 number percent, usually at least 60 number percent are ionic amino acids and usually not more than 90 number percent are ionic amino acids.
  • the ionic amino acids are: basic, K and R; acidic, D and E.
  • compositions having at least about 60 amino acids will have the charged domains separated by at least 25 amino acids, usually at least 40 amino acids and fewer than about 70 , usually fewer than about 65 amino acids.
  • the amino acid linking sequence separating the charged domains will usually have an excess of cationic over anionic amino acids, generally having from about a 1.5 to 3, usually about 2, to 1 ratio, with the pK of the compound in the range of about 6.5 to 8, particularly about 7.4.
  • the bridging disulfides are from about 20 to 45, usually 22 to 40 amino acids apart, preferably separated by about 25 and 39 amino acids.
  • the cysteines proximal to the N-terminus will be from about 8 to 16 amino acids from the N-terminus, with the cysteines proximal to the C-terminus about 12 to 45 amino acids, usually 16 to 40 amino acids, from the C-terminus.
  • compositions of interest will usually have a sequence proximal to the N-terminus, which has the formula of the pentapeptide E-A-E-E-D, more usually the decapeptide E-A-E-E-D-G-D-L-Q-C, frequently the pentadecapeptide E-A-E-E-D-G-D-L-Q-C-L-C-V-K-T, and more frequently having the following formula: E-A-E-E-D-C-D-L-Q-C-L-C-V-K-T-T-S-Q-V-R-P-R-H- where the letters have the following meaning in accordance with convention:
  • V - valine Compositions of interest will usually have proximal to the C-terminus, a sequence of the formula K-K-I-I-K-K, more usually a sequence of the formula K-K-I-I-K-K-L-L, and preferably P-L-Y-K-K-I-I-K-K-L-L-E-S .
  • insertions or deletions may be involved, where usually insertions or deletions will involve from 1 to 2 amino acids, particularly 1 amino acid.
  • Novel polypeptides of interest will for the most part have the following formula:
  • Ac R is the N-terminal region and is characterized by having from 10 to 20 amino acids of which from four to five are acidic, at least two of the first three amino acids are acidic, two acidic amino acids are in tandem and a different two acidic amino acids are separated by a neutral aliphatic amino acid; two cys residues are present separated by a single neutral aliphatic amino acid; the cys-X-cys is separated from D or E-X-D or E by from two to six amino acids;
  • M is the middle region, either being a short linking group of from 2 to 30 carbon atoms, or having from about 25 to 40 amino acids; having two cysteines separated from the cysteines of Ac R by at least 10, usually at least 20, amino acids and each of these cysteines forming a disulfide bridge with one of the cysteines in Ac R ; having from five to seven basic amino acids and from two to five, usually three to four, acidic amino acids; Ba r (basic region) is the C-terminal region and is characterized by having from 12 to 30 amino acids; having two pairs of basic amino acids each succeeded by from two to three neutral aliphatic amino acids, either polar or non-polar, usually non-polar; having a proline from 10 to 15 amino acids from the C-terminal amino acid.
  • Ac R will have the following formula:
  • (H) intends hydrogen at the N-terminus
  • aa 1 , 3 may be a bond or an aliphatic amino acid of from 2 to 6 carbon atoms, usually an acidic amino acid or a non-polar amino acid of from 2 to 3 carbon atoms
  • aa 2 may be a bond or an aliphatic ammo acid of from 2 to 6 carbon atoms, usually a basic amino acid, polar amino acid of from 3 to 5 carbon atoms, or a non-polar amino acid of from 2 to 3 carbon atoms
  • X 1 is a bond or amino acid sequence of from 1 to 2 amino acids of from 2 to 6 , usually 4 to 6 carbon atoms, which are aliphatic non-polar or polar amino acids
  • aa 6 is an aliphatic amino acid of from 2 to 6, usually 2 to 4 carbon atoms which may be non-polar or polar, or an acidic amino acid
  • aa 8 is an aliphatic amino acid of from 2 to
  • aa 9 is an aliphatic amino acid of from 2 to 6, usually 4 to 6 carbon atoms, particularly polar carboxamide substituted or basic
  • X 2 is a bond or an amino acid sequence of from 1 to 2 aliphatic amino acids of from 2 to 6 carbon atoms particularly neutral amino acids
  • aa 11 is an aliphatic amino acid of from 2 to 6, usually 3 to 6 carbon atoms, which may be non-polar or polar
  • aa 13 is an aliphatic amino acid of from 2 to
  • X 3 is a bond, an hydroxyl, alkoxyl group of from 1 to 3 carbon atoms, amino, or an amino acid sequence of from 1 to 6, usually 1 to 3 amino acids, usually neutral aliphatic and either non-polar or polar, particularly polar, the first three amino acids normally being neutral, wherein X 3 may terminate the molecule or be a link to M R, Ba R or an antigen.
  • Preferred amino acids for the symbols are as follows: aa 1 - bond, D, E, G, A aa 2 - bond, G, A, K, R, S, T
  • aa 40,56 are an alipuhatic acidic ammo acid or amide thereof of from 4 to 5 carbon atoms
  • aa 41,42,'51,'53,'63,64,67 are aliphatic ammo acids, particularly non-polar, of from 2 to 6 , more particularly of from 5 to 6 carbon atoms
  • aa 45 is an aliphatic amino acid of from 2 to 6 carbon atoms, particularly non-polar of from 4 to 6 carbon atoms, or a basic amino acid
  • aa 47 is an aliphatic amino acid of from 3 to
  • aa 55 is a neutral aliphatic amino acid of from 2 to 6 carbon atoms, either non-polar, particularly of from 4 to 6 carbon atoms, or polar of from 4 to 5 carbon atoms having a carboxamide functionality;
  • aa 57 is an aliphatic amino acid of from 2 to
  • aa 59 is an aliphatic amino acid of from 2 to
  • X 4 is an hydroxyl, alkoxyl of from 1 to 3 carbon atoms, amino, or an amino acid sequence of from 1 to 4, usually 1 to 2, amino acids, particularly aliphatic amino acids, more particularly polar and acidic amino acids, having from 0 to 1 non-polar amino acid of from 2 to 3 carbon atoms, from 0 to 3 acidic amino acids, and from 0 to 3 hydroxyl substituted aliphatic ammo acids, wherein X 4 may terminate the molecule or be a link to an antigen or immunoglobulin.
  • M r will include a sequence of at least about 15 amino acids included in the following formula:
  • aa 32 is an aliphatic amino acid of from 2 to 6 carbon atoms, either non-polar of from 2 to 3 carbon atoms, or basic
  • aa 34 is an aliphatic amino acid of from 2 to
  • aa 37 is an aliphatic amino acid of from 2 to
  • X 5 is a bond, hydroxyl, alkoxy of from 1 to 3 carbon atoms, wherein X 5 may terminate the sequence, be a link to Ba R or to an antigen.
  • Analogs of the above composition will usually have at least about 80%, more usually at least about 85%, and preferably at least about 90% of the same amino acids in the above sequence or portion of the above sequence.
  • the naturally occurring polypeptide compositions employed in this invention can be obtained in high purity as established by sensitive bioassays.
  • the naturally occurring polypeptide compositions will have less than about 20%, more usually less than about 10%, and preferably less than about 5% by weight of polypeptides other than the major constituent present in the composition, which contaminating polypeptides are associated with platelets.
  • the polypeptides compositions of this invention demonstrate a variety of physiological activities.
  • the subject compositions can be used to inhibit tumor growth in vitro and in vivo.
  • the subject compositions can also be used to stimulate autophosphorylation of ⁇ p 60 src.
  • Subject compositions may thus serve as a substrate for the pp 60 src enzyme and can be phosphorylated at the tyrosine position (residue 60) in the polypeptide.
  • tumor cells can be induced to release a 52kDal protein when treated with Oncostatin-A.
  • Oncostatin-A or analogs, fragments thereof, or fusion proteins containing sub-sequences (fragments) having competitive immunological properties can be used to produce monoclonal antibodies or act as a reagent in diagnostic assays for the detection of Oncostatin-A or immunologically competitive compounds or the presence of cell surface receptors for Oncostatin-A.
  • the subject compounds have high activity for tumor inhibition.
  • the subject compositions can be used in vitro or in vivo for reducing the rate of growth of neoplastic cells.
  • the polypeptide compositions can provide at lng levels at least about 20% inhibition of tumor cell growth, particularly of carcinomas and sarcomas, e.g., of the lung, breast, skin, etc.
  • the polypeptide compositions will provide at least about 40%, and more preferably at least about 50%, inhibition of tumor cell growth in accordance with the colony inhibition test described in the Experimental section.
  • the subject compositions can be used in vivo by being administered to a host suspected of having neoplasia.
  • the subject compositions can be applied to a neoplastic site, e.g., a melanoma, to reduce the rate of proliferation.
  • Methods of application may include injection, introduction by catheter, direct application, or the like, depending upon the site of the tumor, the formulation of the subject composition, the dosage level and the like. Dosage will vary depending upon whether it is systemic or local, with dosage concentrations generally being from about 0.1 ⁇ g to 1,000yg/Kg and total dosages for large mammals including primates of from about 0.01 to 10mg per treatment dose.
  • Oncostatin-A like materials including Oncostatin-A and its congeners (compounds sharing at least one physiological property of Oncostatin-A and including at least one amino acid sequence having substantially the same amino acid sequence of Oncostatin-A, where the congener may be of greater or lesser amino acid number than Oncostatin-A), can be formulated in physiologically acceptable carriers, such as phosphate buffered saline, distilled water, excipients, or the like, or may be employed neat.
  • physiologically acceptable carriers such as phosphate buffered saline, distilled water, excipients, or the like, or may be employed neat.
  • Oncostatin-A and its congeners may be employed indirectly for detecting the presence of neoplastic cells.
  • concentrations of the active agent of from about 1 to 500ng/ml, preferably from about 50 to 350ng/ml of the active agent
  • p52 52kDal protein
  • Oncostatin-A can therefore be used to monitor the state of a host and the existence or absence of a neoplastic condition.
  • Oncostatin-A can be used in diagnosing whether a tumor exists, in monitoring surgery, levels of metastasis, or the like.
  • the Oncostatin-A like substance would be administered in vitro or in vivo (culture medium or host) in a sufficient amount to provide for induction of the secretion of p52. Fluid associated with the system would then be monitored for the presence of p52 as an indication of the presence of neoplastic cells.
  • Oncostatin-A like materials can also be used to stimulate the immune system, either by itself, but preferably in conjunction with other lymphokines, e.g., interferon, more particularly, ⁇ -interferon.
  • the Oncostatin-A like materials may be formulated with other polypeptides and administered to a host which is immunosuppressed, so as to stimulate the immune system.
  • Gamma-interferon is known to induce la expression in monocytes and macrophages, as well as other tissues, such as endothelium and fibroblasts.
  • the Oncostatin-A like materials induce la expression and stimulate the ⁇ -interferon la induction, enhancing the efficacy of a given dose of ⁇ -interferon.
  • the amount of Oncostatin-A like materials will generally be employed to provide a concentration in the medium in the range of about 1 to 200, preferably about 2 to 70ng/ml.
  • ⁇ -interferon will be conventional as to its use as a lymphokine, generally being in the range of about 0.5 to 200ng/ml. Enhancements in expression of la of at least about 1.5, usually at least 2-fold, can be achieved with Oncostatin-A like materials, when used by itself or in conjunction with other lymphokines. Administration may be employed as described previously.
  • the Oncostatin-A like materials can also be used in conjunction with kinases, particularly pp60 src to change the substrate specificity of the enzyme.
  • kinases particularly pp60 src
  • the kinase activity may be enhanced, including a change in the observed amino acids which are phosphorylated, particularly, besides tyrosine being phosphorylated, serine is also phosphorylated.
  • the combination of pp60 src or analogous kinases may be used for modifying polypeptides having tyrosine and serine amino acids, by providing for phosphorylation of both tyrosine and serine at enhanced rates.
  • the subject Oncostatin-A like materials may also be used as haptens or antigens, as haptens linked to an immunogenic potentiator, e.g., an antigen, particle or the like, for production of monoclonal antibodies or polyclonal sera.
  • the antibodies can find wide use, particularly for diagnostic purposes.
  • the antibodies may be used by themselves or in conjunction with Oncostatin-A like materials as reagents for the detection of Oncostatin-A and Oncostatin-A receptors, including antibodies to Oncostatin-A.
  • Oncostatin-A like materials as reagents for the detection of Oncostatin-A and Oncostatin-A receptors, including antibodies to Oncostatin-A.
  • a wide variety of protocols and techniques are available for determining analytes of interest. These techniques involve a wide variety of labels, including enzymes, radionuclides, fluorescers, chemi- luminescers, enzyme substrates, enzyme inhibitors, particles, and the like.
  • the methods may involve a separation step (heterogeneous) or no separation step (homogeneous) .
  • the label may be covalently bonded to either the Oncostatin-A like material or the antibody to Oncostatin-A like material (anti-Oncostatin-A) or may be conjugated to an antibody directed to the anti-Oncostatin-A, for example, to the Fc of the anti-Oncostatin-A.
  • the whole antibody may be used or fragments thereof, including Fab, F(ab)'2'' Fv, or the like.
  • a number of United States patents have issued describing a wide variety of diagnostic techniques which may be used in this invention. Exemplary of a few of these patents are U.S. Patent Nos. 3,766,162; 3,791,932; 3,817,837; 3,996,345; and 4,233,402.
  • Particular types of assays include RIA, EIA, EMIT ® ,
  • ELISA ELISA
  • SLFIA SLFIA
  • FIA FIA
  • the various reagents may be provided in kits where the nature of the reagents and their relative amounts are selected for optimizing the sensitivity of the assay.
  • the antibodies may be prepared in conventional ways in accordance with the preparation of monoclonal antibodies or polyclonal sera.
  • an appropriate host will be injected with an immunogen having one or more epitopic sites of interest, usually followed by one or more booster injections.
  • the host may be bled and the globulin fraction isolated. The globulin fraction may be further purified by affinity chromatography.
  • the host will be immunized as before, but in this instance the spleen will normally be removed and fused with an appropriate fusion partner. After selection of hybridomas expressing the desired antibody, the hybridomas will be subjected to limiting dilution, followed by selection and cloning, and further characterization.
  • the antibodies according to this invention may be any of the types which naturally occur, such as
  • IgA, IgD, IgE, IgG and IgM particularly IgM and the various subtypes of IgG, i.e., IgGl, 2, 3 or 4.
  • the resulting monoclonal antibodies can be used as immunogens for production of anti-idiotype antibodies which will have conformational similarity to the Oncostatin-A type materials. These may then be used as substitute reagents for Oncostatin-A type materials in a variety of applications.
  • Oncostatin-A can be obtained by extraction of platelets with approximately 0.3M ethanolic hydrochloric acid.
  • phenylmethylsulfonyl fluoride and aprotinin may also be included, the former at levels of about 1-10% by weight of the extracting composition and the latter at levels of about 0.1-1TIU/mg (TIU--trypsin inhibition units) of the extracting composition.
  • aqueous ammonium hydroxide After raising the pH to about 5, using aqueous ammonium hydroxide, a small amount of ammonium acetate is added and the solution clarified by centrifugation or other convenient means.
  • the protein is then precipitated by successively employing cold ethanol (95%) and ether, the precipitate collected and dialyzed against 0.1-0.5M acetic acid employing a dialysis membrane having a cutoff below about 3,000Mr.
  • the residue is lyophilized, resuspended in 1M acetic acid, clarified and is then ready for further purification by gel permeation chromatography employing Biogel P-10.
  • the product is eluted with about 1M acetic acid and the various fractions monitored employing an appropriate assay technique, e.g., tumor growth inhibition.
  • the fractions having the growth inhibiting activity are lyophilized, resuspended in dilute aqueous trifluoroacetic acid, pH 2-3, clarified and then chromatographed on a high pressure, liquid chromatograph, where the silica packing has a coating of a long aliphatic chain of from about 16 to 20 carbon atoms, e.g., 18 carbon atoms.
  • the column is equilibrated with dilute trifluoroacetic acid (0.02-0.1%) and the product eluted with an acetonitrile gradient of up to 60% acetonitrile in dilute (0.01-0.1, usually about 0.04-0.05%) trifluoroacetic acid.
  • a relatively slow flow rate is employed, generally about 0.5 to lml/min at ambient temperatures.
  • the fractions may be assayed by the bioassay indicated previously or other bioassays.
  • the product obtained from the column may be purified utilizing high pressure gel exclusion chromatography.
  • the major peak of Oncostatin-A activity resolved by Novapak C 18 reverse phase liquid chromatography is lyophilized and resuspended in 100 ⁇ l of 40% acetonitrile containing 0.1% trifluoroacetic acid.
  • the sample is injected into a hydroxylated polyether gel column (Bio Rad TSK-250) and eluted with a mobile phase consisting of 40% acetonitrile in 0.1% trifluoroacetic acid.
  • the product obtained from the column may be electrophoresed employing SDS-PAGE.
  • the band at about 6,000-8,000 molecular weight is isolated.
  • the band is shown to have strong growth inhibitory activity against neoplastic mammalian cells.
  • Oncostatin-A may be prepared by hybrid DNA technology.
  • the structural gene for Oncostatin-A can be obtained from the host cell genome employing probes prepared based on the amino sequence.
  • a genomic library may be searched using the probe (which may be appropriately redundant), hybridizing fragments isolated and the fragments reduced in size and characterized by restriction mapping and sequencing.
  • a DNA may be searched analogously to the genomic library and if complete or partial structural genes isolated these can be used, the latter by employing an adapter to replace the missing codons.
  • a synthetic gene may be synthesized.
  • the termini of the gene are different to ensure the proper orientation upon insertion.
  • the gene may be inserted into an appropriate expression vector for expression.
  • a large number of vectors are available for expression in prokaryotes and eukaryotes, such as fungi, e.g., yeast, mammalian cells, e.g., mouse cells, primate cells, etc.
  • the replication system may be derived from plasmids, viruses or chromosomes. Illustrative replication systems include ColEl, lambda, RSF1010, 2 ⁇ m plasmid, SV40, adenovirus, papilloma bovine virus, etc.
  • a marker will usually be present which allows for selection of the host containing the desired gene.
  • the marker will usually provide biocide resistance, e.g., antibiotics or heavy metals or complementation, prototrophy to an auxotrophic host.
  • One or more markers may be present, usually not more than three.
  • the structural gene will be located, usually by insertion into a polylinker (a sequence having a plurality of restriction sites), between transcriptional and translational initiation and termination regulatory regions recognized by the expression host.
  • a polylinker a sequence having a plurality of restriction sites
  • transcriptional initiation region transcription may be constitutive or inducible.
  • a large number of promoter regions have been isolated and shown to be useful, such as the E. coli trp and lac promoter, the lambda P L and P R promoters, the yeast glycolytic enzyme promoters, the SV40 and adenovirus early and late promoters, and the like.
  • a fused gene may be prepared by providing a 5'-sequence to the structural gene which encodes a secretory leader and processing signal.
  • secretory leaders which have been described include the secretory leaders of penicillinase, ⁇ -factor, immunoglobulins, T-cell receptors, outer membrane proteins, and the like. By fusion in proper reading frame the mature Oncostatin-A or congener may be secreted into the medium.
  • the construct containing the structural gene and flanking regions providing regulations of expression may be introduced into the expression host by any convenient means, e.g., transformation, with for example, calcium phosphate precipitated DNA, transfection, transduction, conjugation, microinjection, etc.
  • the host may then be grown to a high density in an appropriate nutrient medium.
  • permissive conditions will then be employed, e.g., temperature change, exhaustion or excess of a metabolic product or nutrient, or the like.
  • the product is retained in the host, the cells are harvested, lysed and the product isolated and purified by extraction, precipitation, chromatography, electrophoresis, etc.
  • the nutrient medium may be collected and the product isolated by conventional ways, e.g., affinity chromatography.
  • the structural gene sequences may be used as probes for hybridization and detection of duplexing sequences. For example, the presence and amount of mRNA may be detected in host cells.
  • DMEM--Dulbecco's modified eagle's medium PBS phosphate buffered saline; P/S--penicillin/streptomycin (0.57mg/ml each); FCS--fetal calf serum; SDS-PAGE--sodium dodecylsulfate polyacrylamide gel electrophoresis.
  • Fresh or frozen platelets (50g wet weight) thawed at room temperature were resuspended in two volumes of: 375ml ethanol (95%), 7.5ml cone. HCl, 33mg phenylmethylsulfonyl fluoride and 1ml of aprotinin (23TIU/ml; from bovine lung--Sigma Chemical Co. A6012).
  • the mixture was stirred at 4°C overnight, centrifuged 8K rpm in Beckman-type 19 rotor for 30min and the supernatant removed.
  • the pH of the supernatant was adjusted with cone, ammonium hydroxide to 4.0 and the pH raised to 5.2 using a 1:10 dilution of cone, ammonium hydroxide.
  • the acetic acid dispersion was dialyzed extensively against 5L X 2 changes of 0.2M acetic acid in a Spectrapor dialysis membrane (#3) tubing (cutoff 3,500Mr) (American Scientific Products).
  • the extract was lyophilized, resuspended in 7.5ml of IM acetic acid, followed by centrifuging at 30K rpm.
  • Biogel P-10 (200-400 mesh; Bio Rad Labs) was swelled overnight in IM acetic acid, degassed thoroughly and then poured into a 100x2.5cm siliconized glass column and allowed to equilibrate overnight with IM acetic acid. All solutions were degassed before using.
  • the fraction containing the peak of tumor growth inhibitory activity (about 200ng of protein) from the above column was lyophilized and resuspended in 0.05% (v/v) of trifluoroacetic acid.
  • the column was then eluted with a linear 0.60% gradient of acetonitrile in 0.045% triluoroacetic acid at a flow rate of 0.8ml/min at 23°C. Aliquots of each fraction were lyophilized and assayed in triplicate, as described above.
  • the fraction (s) containing the inhibitory activity were then dissolved in 40% acetonitrile containing 0.1% trifluoroacetic acid and applied to a hydroxylated polyether gel column (Bio Rad TSK-250) and eluted with a mobile phase of 40% acetonitrile in 0.1% trifluoroacetic acid. Fractions were collected, lyophilized and assayed in triplicate for growth inhibitory activity. The activity elutes in the fraction where the insulin marker elutes and corresponds to a molecular weight of 6-8kDal.
  • the peptide corresponding to the major Oncostatin-A activity from the reverse phase HPLC purification step was lyophilized, resuspended and boiled (2min) in 0.03ml of a sample preparation buffer containing 12.5mM Tris-C1 pH 6.7, 4% SDS, 10% ⁇ -mercaptoethanol, 20% glycerol and 0.01% bromphenol blue.
  • the sample was loaded onto a 5% polyacrylamide stacking gel poured over a 17 to 27% polyacrylamide gradient slab gel containing 0.1% SDS, at pH 8.8. The get was run at 10 milliamps until samples migrated through the stacking gel and at 20 milliamps until the dye front migrated to the bottom of the gel.
  • the assay employed was as follows: On day 2 in the morning A549 cells (human lung carcinoma) in Nunc 96 well plates (Kamstrupvej 90. DK-4,000, Roskilde, Denmark) were set up. These cells were passaged when there were fewer than 30. Into all but the peripheral wells was introduced 45,000 cells/50 ⁇ l/well (9x10 4 cells per ml DMEM with 10% FCS, P/S, glutamine). The peripheral wells received 50 ⁇ l PBS and the entire plate was incubated at 37°C. In the afternoon, the test samples were resuspended in DMEM with 10% -FCS, P/S, glutamine triplicate testing. Into each test well was delivered 50 ⁇ l, while control wells received 50 ⁇ l DMEM and the plate incubated at 37°C for 3 days. On day 4, into each well 50ml of a solution of
  • Oncostatin-A prepared above the following test was carried out.
  • the test is referred to as soft agar colony inhibition.
  • the materials employed are 5% agar
  • FCS 100U penicillin, 100U streptomycin, 200mM glutamine, and human melanoma cells (A375) .
  • Materials to be tested are lyophilized in a sterile 12x75mm test tube. A 1:10 dilution of the 5% agar is made with DMEM and heated to 46°C in a water bath. A base layer is prepared by pipetting 1ml of
  • agar solution 0.5% agar solution into each well of a 6-well culture plate (35x14mm) .
  • the layer is allowed to stand at room temperature until it hardens.
  • SA 6 cells are prepared by trypsinizing and the number of cells counted. The cells are diluted to a final concentration of 1x10 4 cells per ml and 0.35ml of cells is added to each test sample tube.
  • test sample tube Into each of ten test sample tubes is pipetted 0.750ml of a 0.5% agar solution, the mixture vortexed gently and the contents of the test sample tube (test sample, cells, agar) is poured onto the base layer and allowed to stand for about 20min at room temperature until the agar hardens. The plates may then be stored in a 37°C humidified incubator with 5% carbon dioxide.
  • the plates are checked for inhibition of colony growth after 3 days and up to 10 days depending on the potency of the test material. The number of colonies is counted in 8 random low power microscope fields. When plates are to be maintained longer than 5 days, another 1ml layer of 0.3% agar solution is overlayed on the test sample layer to prevent drying of the test sample layer.
  • the above procedure was employed using varying concentrations of the purified Oncostatin-A. The following table indicates the results, the amount of Oncostatin-A indicated being the lyophilized amount introduced into the test tube. The results are reported as percent maximal inhibition.
  • the subject polypeptide is a potent inhibitor of cell growth. Based on the results observed with the melanoma cells, about Ing is sufficient to provide about 50% inhibition.
  • the subject compound can, therefore, find a wide variety of uses in inhibiting cellular growth, including neoplastic cellular growth.
  • the subject compound also inhibits a variety of cultured human tumor cells, but not normal non-neoplastic human foreskin fibroblasts, as evidenced in the following table.
  • mice Young (8-10 weeks) athymic mice were injected subcutaneously in the inguinal region with 5x10 6 human lung carcinoma cells (A549) suspended in 100 ⁇ l of phosphate buffered saline (PBS) . Seven days post inoculation palpable tumors developed 2.5-3.0mm in diameter; tumor bearing mice were randomly selected from this population and injected on day 7 subcutaneously on the tumor site with 50 ⁇ l of PBS containing 0.30 ⁇ g of Oncostatin-A purified to homogeneity from human platelets, as described previously. Injection of tumor bearing control mice with PBS without Oncostatin-A did not effect tumor growth.
  • PBS phosphate buffered saline
  • Tumor bearing mice were then subsequently injected with an equivalent dose of Oncostatin-A in 50 ⁇ l of PBS at days 11 and 16 post-inoculation of A549 cells. These doses of Oncostatin-A were injected directly into the tumor mass utilizing a 301 ⁇ 2"g needle. Tumor size was monitored at the days indicated by measuring tumors in both the horizontal and vertical dimensions with calipers ; (a) tumor size noted on the ordinate represents multiples of these two dimensions. The results are depicted in Fig. 1.
  • Human lung carcinoma cells (A549) were treated with Oncostatin-A (200ng/ml of culture) and the effect on polypeptides released into the cell culture supernatant was determined. Treated and control cultures (no Oncostatin-A) were pulsed with
  • Radioautography of the gel demonstrated the presence of a 52,000Mr 35 S-methionine labeled polypeptide in supernatants derived from A549 cells treated with Oncostatin-A, whereas untreated cancer cells released minimum amounts of this protein (at least a ten-fold increase was seen after Oncostatin-A treatment). No other qualitative or quantitative differences were seen between treated or control cultures.
  • Wehi-3 is a mouse macrophage cell line which can be induced by gamma interferon ( ⁇ -IFN) to express H2 class II antigens.
  • ⁇ -IFN gamma interferon
  • the features of this induction have been studied by several laboratories and shown to be an accurate replica of normal macrophage induction.
  • These cells were grown either with or without a low amount of ⁇ -IFN with several concentrations of platelet Oncostatin-A. Both in the presence or absence of ⁇ -IFN, Oncostatin-A showed a dose dependent enhancement of class II antigen as measured by direct immunofluorescence on a FACS.
  • the magnitude of the Oncostatin-A effect was generally twofold at the concentrations employed ( ⁇ 2-70ng/ml).
  • Oncostatin-A The procedure for cross-linking Oncostatin-A to bacterial lipopolysaccharide is a modification of the method developed by Primi and Cazenave, J. Immunol. (1982) 129(3):1124-1129.
  • Ten ng of Oncostatin-A and 12.5ng of bacterial lipopolysaccharide (LPS; Sigma #L-263) was diluted to a volume of 500 ⁇ l with distilled water.
  • Fifty ⁇ l of 2.5% glutaraldehyde in PBS was added and the mixture was incubated for 30min at room temperature.
  • the reaction was stopped by adding 50 ⁇ l of 2M glycine in PBS and incubating the mixture at room temperature for lhr.
  • the Oncostatin-A: LPS conjugate was diluted with 10ml of mixed lymphocyte conditioned medium and a filter sterilized for use in an in vitro immunization.
  • Non-immune splenocytes were immunized in vitro using a modification of the procedure described by Reading, Immunol. Meth. (1982) 53:261-269.
  • MLC Mixed lymphocyte conditioned
  • PEC Peritoneal exudate cells
  • the immune splenocytes were collected and fused with SP2/0 myeloma cells at a ratio of 1:1 to produce hybridomas which synthesize Oncostatin-A specific monoclonal antibodies.
  • the hybridomas were tested for production of Oncostatin-A antibodies by an enzyme linked immunoassay (ELISA). Positive hybridomas were cloned twice by limiting dilution. Clones were expanded, tested for immunoglobulin class, and injected into Balb/c mice for ascites production.
  • Oncostatin-A was diluted in 0.1M acetic acid and lOng/well was pipetted into a 96 well Dynatech Immulon plate. The solution was dried down overnight at room temperature. The plate was blocked by incubation of the wells with 2.5% BSA, 2.5% fetal bovine serum (FCS) in PBS at 37°C for lhr. The plate was then washed twice with 2.5% FCS in PBS. The hybridoma medium, immunoglobulin or antiserum was then added at the appropriate dilution. The plates were then incubated at 37°C for two hours and washed three times with 2.5% FCS in PBS.
  • FCS fetal bovine serum
  • Balb/c mice were immunized with nitrocellulose immobilized Oncostatin-A.
  • the purpose of this immunization protocol is to avoid rapid clearance of the polypeptide by the host. In this way, immunization can be effected by very small amounts of Oncostatin-A.
  • Oncostatin-A in 0.1M acetic acid was dotted onto small pieces of nitrocellulose (Schleicher & Schuell , 0 . 45 ⁇ m) and allowed to dry .
  • the pieces of nitrocellulose were placed into the peritoneal cavity of three Balb/c mice for the initial immunization (0.375ng/mouse).
  • the mice were also given an intraperitoneal injection of 0.1ml complete Freund's adjuvant.
  • the mice were boosted twice at two-week intervals with Oncostatin immobilized nitrocellulose. For boosts, the nitrocellulose was chopped up, homogenized with 0.1ml water and 0.1ml incomplete Freund's adjuvant and injected subcutaneously (0.125ng/mouse).
  • mice sera were tested for specificity against Oncostatin-A by the ELISA assay previously described, with horseradish peroxidase conjugated protein A used as the second step reagent.
  • the sera were tested against Oncostatin-A peptide - KLH conjugate and a blocked plate to show specificity.
  • GGC GCC ATG GAA GCT GAA GAA GAC GGA GAT CTG CAG TGC -39 met glu ala glu glu asp gly asp leu gln cys / NH 2
  • the sequence is designed for usage in E. coli and a number of restriction enzyme recognition sites were devised to allow for ease of modification of the coding sequence.
  • Single stranded overlapping sequences were prepared, combined in an annealing medium and ligated to provide the complete gene with appropriate termini for insertion into an expression vector in reading phase to prepare a fused protein from which Oncostatin-A could be isolated.
  • the single stranded segments are 5'-phosphorylated with T4 polynucleotide ligase and annealed by combining 200 pmoles of each segment in a 30 ⁇ l reaction volume (30mM ATP, 10mM DTT, 10mM MgCl 2 , 1 ⁇ g/ml spermidine, 100mM tris-HCl, pH 7.8 and T4 DNA ligase.
  • the dsDNA is digested with BssHII and BamHI and purified on a 7% native polyacrylamide gel.
  • the plasmid ptrpED5-1 (Hallewell and Entage, Gene (1980) 9:27; Tacon et al., Mol. Gen. Genet. (1980) 177:427) is digested with endonucleases BssHII and BamHI and a substantially full length fragment lacking the trp D gene and having a truncated trp E gene is isolated by preparative gel electrophoresis.
  • the Oncostatin-A gene is ligated to the linearized ptrpED5-1 plasmid to provide plasmid ptrp(Onc-A) and the ligation mixture is used to transform E. coli HB101 cells.
  • Transformants are selected by ampicillin resistance and the plasmids analyzed by restriction endonuclease digestion. The transformants are grown at 37°C to about 10 8 cells/ml in Luria broth and 3-indolylacetic acid (IAA) is added to about 1mM and growth continued for about lhr.
  • IAA 3-indolylacetic acid
  • Oncostatin-A has no internal methionine, having an N-terminal methionine cleavage of the fused protein provides Oncostatin-A having the same amino acid sequence as naturally occurring Oncostatin-A. It is evident from the above results that the subject compounds find a wide variety of applications. Particularly, the compounds can be used in the diagnosis and treatment of neoplastic states.
  • the compounds can provide for the slowing of tumor cell growth, so as to be used jointly with other modes of treatment for the destruction of tumor cells.
  • the subject compounds are found to induce the production of p52, so that upon administration of the subject compounds to a host, enhanced levels of p52 would be indicative of the presence of tumor cells. This can be very important during the treatment of a neoplastic state to determine whether the removal of the tumor cells has been successful or metastases have occurred.
  • the subject compounds can also be used as reagents in diagnostic assays for the presence of Oncostatin-A or Oncostatin-A receptors.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Nouvelles compositions polypeptidiques inhibant la croissance des cellules tumorales humaines, pouvant ou non stimuler l'autophosphorylation de pp60 src et induire la libération d'un polypeptide 52kDal à partir de cellules néoplastiques. Des polypeptides séparés peuvent être isolés de thrombocytes sanguins de mammifères par des procédures d'extraction et de purification, synthétisés ou produits par la technologie de l'ADN hybride.
PCT/US1985/000480 1984-03-15 1985-03-19 Regulateur de croissance apparente aux thrombocytes WO1985004397A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
HU852180A HU210662B (en) 1984-03-23 1985-03-19 Method for production of a conposition inhibiting tumor cell growth and for delection of tumor cells
KR1019850700309A KR910000735B1 (ko) 1984-03-15 1985-03-19 혈소판 관련 증식 제어물질
EP85902216A EP0176588B1 (fr) 1984-03-23 1985-03-19 Regulateur de croissance apparente aux thrombocytes
JP60501854A JPH0816063B2 (ja) 1985-03-15 1985-03-19 腫瘍細胞増殖阻害剤
DE3587863T DE3587863T2 (de) 1984-03-23 1985-03-19 Mit thrombozyten verwandter wachstumregulator.
FI854604A FI92258C (fi) 1984-03-23 1985-11-21 Onkostatiini-A:n käyttö diagnostisessa menetelmässä
DK198505406A DK172463B1 (da) 1984-03-23 1985-11-22 Anvendelse af oncostatin-A eller derivater deraf til in vitro diagnostisk detektion af tumorceller
FI940457A FI940457A0 (fi) 1984-03-23 1994-01-31 Menetelmä onkostatiini-A:n valmistamiseksi

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US06/592,969 US4590003A (en) 1984-03-23 1984-03-23 Platelet related growth regulator
US592,969 1984-03-23
US06/712,302 US4645828A (en) 1984-03-23 1985-03-15 Platelet related growth regulator
US712,302 1991-06-07

Publications (1)

Publication Number Publication Date
WO1985004397A1 true WO1985004397A1 (fr) 1985-10-10

Family

ID=27081584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1985/000480 WO1985004397A1 (fr) 1984-03-15 1985-03-19 Regulateur de croissance apparente aux thrombocytes

Country Status (10)

Country Link
US (1) US4645828A (fr)
EP (1) EP0176588B1 (fr)
JP (2) JPH0242985A (fr)
AT (1) ATE107662T1 (fr)
AU (1) AU587380B2 (fr)
DE (1) DE3587863T2 (fr)
DK (1) DK172463B1 (fr)
FI (1) FI92258C (fr)
HU (1) HU210662B (fr)
WO (1) WO1985004397A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281363A2 (fr) * 1987-03-02 1988-09-07 Oncogen Régulateur de croissance lie aux plaquettes sanguines
EP0301458A2 (fr) * 1987-07-30 1989-02-01 New York University Composition contenant un fragment de facteur plaquettaire IV et méthode de restauration de l'immunité
EP0324556A2 (fr) * 1988-01-14 1989-07-19 Nippon Mining Company Méthode d'amélioration de la translation de mRNA et son application pour la production du facteur de trombocyte-4
EP0378364A2 (fr) * 1989-01-10 1990-07-18 Repligen Corporation Analogues de PF4 et leurs fragments et compositions pharmaceutiques les contenant
EP0407122A1 (fr) * 1989-07-06 1991-01-09 Repligen Corporation Compositions de PF4 modifié et méthode d'utilisation
EP0457532A1 (fr) * 1990-05-14 1991-11-21 FIDIA S.p.A. Anticorps monoclonal inhibant l'action biologique du facteur plaquettaire 4
US5248666A (en) * 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
EP0576669A1 (fr) * 1992-01-16 1994-01-05 Repligen Corporation Nouveaux procedes et compositions de traitement des maladies angiogeniques
WO1994005309A1 (fr) * 1992-08-28 1994-03-17 University Of Louisville Research Foundation, Inc. Utilisation du facteur plaquettaire 4 pour empecher la proliferation des osteoblastes
EP0749475A1 (fr) * 1992-08-26 1996-12-27 The President And Fellows Of Harvard College Utilisation de la cytokine ip-10 comme agent antitumeur
US5759547A (en) * 1989-01-10 1998-06-02 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
US6037446A (en) * 1990-11-28 2000-03-14 Envision Gestational agents for controlling cell proliferation
WO2010040766A1 (fr) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps neutralisants et fragments de ceux-ci orientés contre un variant 1 de facteur de plaquette 4 (pf4v1)
WO2011012585A1 (fr) 2009-07-29 2011-02-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides mutants pf4 présentant une activité antigiogénique accrue
WO2012101125A1 (fr) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps spécifiques dirigés contre le cxcl4 humain et leurs utilisations

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294172B1 (en) 1983-08-12 2001-09-25 Dade Behring Marburg Gmbh Monoclonal antibodies with specificity for membrane-associated antigens
EP0487116B1 (fr) * 1984-10-12 1999-12-29 ZymoGenetics, Inc. Analogues biologiquement actifs d'un facteur de croissance provenant de plaquettes sanguines dans des cellules eucaryotiques
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5498600A (en) * 1984-10-12 1996-03-12 Zymogenetics, Inc. Biologically active mosaic proteins
US5187263A (en) * 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
US4849407A (en) * 1986-08-13 1989-07-18 Zymogenetics, Inc. Biologically active mosaic proteins
US5045633A (en) * 1985-02-25 1991-09-03 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits
ATE76311T1 (de) * 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
JPH0739489B2 (ja) * 1987-03-06 1995-05-01 東ソー株式会社 ポリアリ−レンスルフイドの製造方法
US5187075A (en) * 1989-01-26 1993-02-16 Sri International Cloning and expression of a variant gene of platelet factor 4 and compositions thereof to modulate immune responses
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
JP3159705B2 (ja) * 1990-12-21 2001-04-23 キュラティブ テクノロジーズ，インコーポレーテッド 血管形成ペプチド
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
FR2671487B1 (fr) * 1991-01-14 1993-03-19 Oreal Utilisation d'un facteur de croissance dans une composition amincissante.
US5543318A (en) * 1991-06-12 1996-08-06 Smith; David A. Method of isolation, culture and proliferation of human atrial myocytes
CZ195193A3 (en) * 1992-09-25 1994-04-13 Lilly Co Eli Modified factor-4 of blood platelets, process of its preparation and pharmaceutical preparation in which it is comprised
AU7209594A (en) * 1993-06-18 1995-01-17 David F. Counts Anti-inflammatory peptides
US6444421B1 (en) * 1997-11-19 2002-09-03 The United States Of America As Represented By The Department Of Health And Human Services Methods for detecting intermolecular interactions in vivo and in vitro

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3791932A (en) 1971-02-10 1974-02-12 Akzona Inc Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4479896A (en) * 1981-12-11 1984-10-30 Antoniades Harry N Method for extraction localization and direct recovery of platelet derived growth factor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RO80052B (ro) * 1977-11-08 1985-03-30 Genetech Procedeu pentru prepararea unui vehicul recombinat de clonare pentru transformarea unei gazde bacteriene pentru a deveni generator de polipeptida heterologa
HUT42101A (en) * 1985-01-07 1987-06-29 Sandoz Ag Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3791932A (en) 1971-02-10 1974-02-12 Akzona Inc Process for the demonstration and determination of reaction components having specific binding affinity for each other
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4479896A (en) * 1981-12-11 1984-10-30 Antoniades Harry N Method for extraction localization and direct recovery of platelet derived growth factor

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Biochimica et Biophysica Acta, Vol. 560, issued 1979, pages 217-241, SCHER, et al. *
ERICKSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 76, 1979, pages 6260 - 6264
HALLEWELL; ENTAGE, GENE, vol. 9, 1980, pages 27
Journal Cell Physiol. Vol. 99, issued 1979, pages 395-406, STILES, et al. *
LAEMMELI, U.K., NATURE, vol. 227, 1970, pages 680 - 685
MORGAN ET AL., THROMB. HAEMOST., vol. 42, 1980, pages 1652 - 60
PRIMI; CAZENAVE, J. IMMUNOL., vol. 129, no. 3, 1982, pages 1124 - 1129
Proceeding National Academy of Science, Vol. 76, issued 1979 pages, 3722-3726, HELDIN, et al. *
Proceeding National Academy of Science, Vol. 76, issued 1979, pages, 1809-1813, ANTONIADES, et al. *
READING, IMMUNOL. METH., vol. 53, 1982, pages 261 - 269
RUSSO ET AL., ANAL. BIOCHEM., vol. 65, 1983, pages 269 - 271
SCHERNTHANER ET AL., ACTA MED. AUSTRIACA, vol. 6, 1979, pages 375 - 9
See also references of EP0176588A4
TACON ET AL., MOL. GEN. GENET., vol. 177, 1980, pages 427

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248666A (en) * 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
EP0281363A3 (en) * 1987-03-02 1988-11-17 Bristol-Myers Company Platelet related growth regulator
EP0281363A2 (fr) * 1987-03-02 1988-09-07 Oncogen Régulateur de croissance lie aux plaquettes sanguines
EP0301458A3 (fr) * 1987-07-30 1990-08-16 New York University Composition contenant un fragment de facteur plaquettaire IV et méthode de restauration de l'immunité
EP0301458A2 (fr) * 1987-07-30 1989-02-01 New York University Composition contenant un fragment de facteur plaquettaire IV et méthode de restauration de l'immunité
US5026639A (en) * 1988-01-14 1991-06-25 Nippon Mining Company, Limited Method to improve mRNA translation and use thereof for production of platelet factor-4
EP0324556A3 (fr) * 1988-01-14 1990-05-30 Nippon Mining Company Méthode d'amélioration de la translation de mRNA et son application pour la production du facteur de trombocyte-4
EP0324556A2 (fr) * 1988-01-14 1989-07-19 Nippon Mining Company Méthode d'amélioration de la translation de mRNA et son application pour la production du facteur de trombocyte-4
EP0378364A2 (fr) * 1989-01-10 1990-07-18 Repligen Corporation Analogues de PF4 et leurs fragments et compositions pharmaceutiques les contenant
US5759547A (en) * 1989-01-10 1998-06-02 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
EP0378364A3 (fr) * 1989-01-10 1992-01-15 Repligen Corporation Analogues de PF4 et leurs fragments et compositions pharmaceutiques les contenant
US5800820A (en) * 1989-01-10 1998-09-01 Repligen Corporation Methods and compositions for treatment of angiogenic diseases
EP0407122A1 (fr) * 1989-07-06 1991-01-09 Repligen Corporation Compositions de PF4 modifié et méthode d'utilisation
EP0723015A1 (fr) * 1989-07-06 1996-07-24 Repligen Corporation Nouvelles compositions de PF4 modifié et procédés d'utilisation
EP0457532A1 (fr) * 1990-05-14 1991-11-21 FIDIA S.p.A. Anticorps monoclonal inhibant l'action biologique du facteur plaquettaire 4
US6037446A (en) * 1990-11-28 2000-03-14 Envision Gestational agents for controlling cell proliferation
EP0576669A1 (fr) * 1992-01-16 1994-01-05 Repligen Corporation Nouveaux procedes et compositions de traitement des maladies angiogeniques
EP0576669A4 (en) * 1992-01-16 1996-05-08 Repligen Corp Novel methods and compositions for treatment of angiogenic diseases
US5935567A (en) * 1992-08-26 1999-08-10 President And Fellows Of Harvard College Cytokine IP-10 as an anti-tumor agent
EP0749475A4 (fr) * 1992-08-26 1997-05-07 Harvard College Utilisation de la cytokine ip-10 comme agent antitumeur
EP0749475A1 (fr) * 1992-08-26 1996-12-27 The President And Fellows Of Harvard College Utilisation de la cytokine ip-10 comme agent antitumeur
US6153600A (en) * 1992-08-26 2000-11-28 President & Fellows Of Harvard College Use of the cytokine IP-10 as an anti-tumor agent
US5304542A (en) * 1992-08-28 1994-04-19 University Of Louisville Research Foundation, Inc. Use of platelet factor 4 to inhibit osteoblast proliferation
WO1994005309A1 (fr) * 1992-08-28 1994-03-17 University Of Louisville Research Foundation, Inc. Utilisation du facteur plaquettaire 4 pour empecher la proliferation des osteoblastes
WO2010040766A1 (fr) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps neutralisants et fragments de ceux-ci orientés contre un variant 1 de facteur de plaquette 4 (pf4v1)
WO2011012585A1 (fr) 2009-07-29 2011-02-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides mutants pf4 présentant une activité antigiogénique accrue
EP2287183A1 (fr) 2009-07-29 2011-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutants PF4 polypeptides exhibiting an increased anti-angiogenic activity
WO2012101125A1 (fr) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps spécifiques dirigés contre le cxcl4 humain et leurs utilisations

Also Published As

Publication number Publication date
FI854604A0 (fi) 1985-11-21
US4645828A (en) 1987-02-24
DK540685D0 (da) 1985-11-22
FI92258B (fi) 1994-06-30
EP0176588A1 (fr) 1986-04-09
AU587380B2 (en) 1989-08-17
DK172463B1 (da) 1998-08-31
DE3587863D1 (de) 1994-07-28
FI92258C (fi) 1994-10-10
AU4235485A (en) 1985-11-01
HUT38300A (en) 1986-05-28
DK540685A (da) 1985-11-22
ATE107662T1 (de) 1994-07-15
FI854604A (fi) 1985-11-21
HU210662B (en) 1995-06-28
DE3587863T2 (de) 1994-10-27
JPH0632631B2 (ja) 1994-05-02
EP0176588A4 (fr) 1989-11-23
JPH0242985A (ja) 1990-02-13
JPH0272896A (ja) 1990-03-13
EP0176588B1 (fr) 1994-06-22

Similar Documents

Publication Publication Date Title
AU587380B2 (en) Platelet related growth regulator
EP0154434B1 (fr) Facteur humain de transformation de croissance et précurseur ou fragment de celui-ci, cellules, ADN, vecteurs et méthodes pour leur production, compositions et produits contenant ceux-ci et anticorps et méthodes diagnostiques en relation avec ceux-ci
US5310661A (en) Nucleic acid encoding the α chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5215893A (en) Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4798885A (en) Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
EP0246753B1 (fr) Antagonistes du facteur de croissance des fibroblastes
EP0366710B1 (fr) Recepteur d'hormone de croissance
EP0281363B1 (fr) Régulateur de croissance lie aux plaquettes sanguines
AU603775B2 (en) Nucleic acid encoding the alpha or beta chains of inhibin and method for synthesizing polypeptides using such nucleic acid
EP0409091A1 (fr) Antagonistes du GM-CSF, dérivés du carboxyl terminal
US4737580A (en) Platelet related growth regulator
US4806492A (en) Polypeptide tumor inhibitors and antibodies thereto
US5248666A (en) Methods for inhibiting neoplastic cell proliferation using platelet factor 4
US4714683A (en) Polypeptide tumor inhibitors and antibodies thereto
EP0178867B1 (fr) Hormones et procédés de production, utilisation et essai de celles-ci
KR910000735B1 (ko) 혈소판 관련 증식 제어물질
JPH0816063B2 (ja) 腫瘍細胞増殖阻害剤

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU DK FI HU JP KR

Kind code of ref document: A1

Designated state(s): AU DK FI HU JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB LU NL SE

Designated state(s): AT BE CH DE FR GB LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985902216

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 854604

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1985902216

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 940457

Country of ref document: FI

WWG Wipo information: grant in national office

Ref document number: 1985902216

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 854604

Country of ref document: FI